Market Engagement Notice for the Licence variation: spironolactone for acne in women

Descriptions

NHS England has published this Preliminary Market Engagement Notice for the Licence variation: spironolactone for acne in women. It is anticipated that there will be two separate contracts to deliver this, as outlined below. • Contract A: Prepare an application for a major (type II) MHRA Marketing Authorisation variation for spironolactone. • Contract B: Submit the pre-prepared application to the MHRA. Only current Marketing Authorisation Holders of spironolactone are eligible to bid for contract B. To register an interest in responding to this market engagement exercise and obtain a copy of the Request for Information documentation please go to: http://health.atamis.co.uk. All communications and Request for Information submissions will be conducted via Atamis.

Engagement

NHS England would like to gather soft intelligence from the market and is publishing a Request for Information for the two contracts. NHS England would also be pleased to offer 1:1 meetings with potential Suppliers to discuss this innovative partnership approach. The Request for Information and further documentation will be available from 25 February 2025 and the deadline for responses and 1:1 meetings will be 12 noon on 11 March 2025.